Drug Trial Radar · NCT00593450
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
Last checked: Nov 20, 2026Latest source record: Aug 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,208
Actual
Start
Feb 2008
Primary completion
Dec 2010
Study completion Apr 2015
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI)
- First posted
- Jan 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule. A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.
Conditions
- Age Related Macular Degeneration
Interventions
ranibizumabDrug
• 0.5 mg (0.05 mL)intravitreal injection
bevacizumabDrug
• 1.25 mg (0.05 mL)intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Visual-acuity Score (Continuous)Time frame: Baseline and 1 Year
Locations
59 sites in 1 country. Site status is shown where the registry gives one.
Retina Consultants of Arizona
Mesa, Arizona
Retinal Consultants of Arizona
Phoenix, Arizona
Retina Associates Southwest, P.C.
Tucson, Arizona
California Retina Consultants
Bakersfield, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California
University of California-Davis Medical Center
Sacramento, California
Retinal Consultants Medical Group, Inc.
Sacramento, California
West Coast Retina Medical Group, Inc.
San Francisco, California
California Retinal Consultants
Santa Barbara, California
West Coast Retina Medical Group, Inc.
Walnut Creek, California
Colorado Retina Associates
Denver, Colorado
Retina Group of Florida
Fort Lauderdale, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Emory Eye Center
Atlanta, Georgia
Illinois Retina Associates
Flossmoor, Illinois
Ingalls Memorial Hospital/Illinois Retina Associates
Harvey, Illinois
Illinois Retina Associates
Joliet, Illinois
Midwest Eye Institute
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Retina Associates of Kentucky
Lexington, Kentucky
University of Louisville School of Medicine
Louisville, Kentucky
Elman Retina Group, P.A.
Baltimore, Maryland
The Retina Group of Washington
Chevy Chase, Maryland
Retina Specialists
Towson, Maryland
Massachusetts Eye & Ear Infirmary
Boston, Massachusetts
Opthalmic Consultants of Boston
Boston, Massachusetts
Harvard Vanguard Medical Associates
Boston, Massachusetts
Vision Research Foundation/Associated Retinal Consultants, P.C.
Grand Rapids, Michigan
Vision Research Foundation/Associated Retinal Consultants, P.C.
Royal Oak, Michigan
Vision research Foundation/Associated Retinal Consultants. P.C.
Traverse City, Michigan
VitreoRetinal Surgery
Edina, Minnesota
Mayo Clinic
Rochester, Minnesota
Barnes Retina Institute
St Louis, Missouri
Retina Vitreous Center, PA
New Brunswick, New Jersey
Retina Vitreous Center, PA
Toms River, New Jersey
Long Island Vitreoretinal Consultants
Great Neck, New York
Long Island Vitreoretinal Consultants
Riverhead, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Charlotte Eye, Ear, nose & Throat Associates
Charlotte, North Carolina
Duke University Eye Center
Durham, North Carolina
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.